Literature DB >> 23163346

The evaluation of cisplatin effect on tubular function in children on chemotherapy.

Soheila Zareifar1, Hamed Jafari, Bita Geramizadeh, Mitra Basiratnia, Habibollah Golafshan, Nader Cohan, Zahra Mehravar, Roghieh Hamidi.   

Abstract

The dose limiting side effect of cisplatin is nephrotoxicity. The aim of this study was to investigate tubular function in children who have received cisplatin and forced diuresis. We performed a cohort study on 20 children under 15 years of age with various type of malignancy on cisplatin-based chemotherapy. Twenty-four-hour urine was collected in three periods: before the first, third, and fifth doses of cisplatin administration to check urine for sodium (Na), magnesium (Mg), uric acid, creatinine (Cr), phosphorus (P), calcium (Ca), beta-2 microglobulin, and N-acetyl-beta-D-glucosaminidase (NAG) levels. At the same time, blood samples were taken to check serum Cr, Na, Mg, Ca, P, and uric acid levels. Then, we compared the mean of glomerular filtration rate (GFR); fraction excretions (FE,%) of Na, Mg, and uric acid; tubular phosphorous reabsorption (TPR,%), 24-hour urine Ca (mg); urine beta-2 microglobulin (mcg/mL); and NAG (IU/L) in three periods of cisplatin administration. The FE of Na, Mg, and urine beta-2 microglobulin increased after administration of cisplatin but TPR, FE, uric acid, and NAG decreased in the 2nd and 3rd period compared to 1st period. GFR revealed a little change that was not significant. Urine calcium was decreased significantly in the second and third periods of cisplatin administration. Since the patients were hydrated for forced diuresis and received magnesium sulfate to prevent nephrotoxicity, we did not see significant tubular dysfunction. But we saw that urine calcium excretion decreased after cisplatin injection without any change in serum calcium in spite of preventive measures.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23163346     DOI: 10.3109/08880018.2012.737093

Source DB:  PubMed          Journal:  Pediatr Hematol Oncol        ISSN: 0888-0018            Impact factor:   1.969


  2 in total

1.  Cisplatinum nephrotoxicity in oncology therapeutics: retrospective review of patients treated between 2005 and 2012.

Authors:  Morgan Finkel; Adam Goldstein; Yael Steinberg; Linda Granowetter; Howard Trachtman
Journal:  Pediatr Nephrol       Date:  2014-08-30       Impact factor: 3.714

Review 2.  Identifying cisplatin-induced kidney damage in paediatric oncology patients.

Authors:  Chris D Barton; Barry Pizer; Caroline Jones; Louise Oni; Munir Pirmohamed; Daniel B Hawcutt
Journal:  Pediatr Nephrol       Date:  2017-08-18       Impact factor: 3.714

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.